Lung cancer and positron emission tomography with fluorodeoxyglucose

Edith M. Marom, Jeremy J. Erasmus, Edward F. Patz

Research output: Contribution to journalArticlepeer-review


Over the past years, positron emission tomography (PET) with fluoro-2- deoxy-D-glucose (FDG) has emerged as an important imaging modality. In the thorax, FDG-PET has been shown to differentiate benign from malignant pulmonary lesions and stage lung cancer. Preliminary studies have shown its usefulness in assessing tumor recurrence, and assisting in radiotherapy planning. FDG-PET is often more accurate than conventional imaging studies, and has been proven to be cost-effective in evaluating lung cancer patients. This review will discuss the current applications of FDG-PET as compared with conventional imaging in diagnosing, staging, and following patients with lung cancer. (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)187-202
Number of pages16
JournalLung Cancer
Issue number3
StatePublished - Jun 2000
Externally publishedYes


  • Diagnosis
  • Lung cancer
  • Positron emission tomography
  • Prognosis
  • Staging
  • Treatment


Dive into the research topics of 'Lung cancer and positron emission tomography with fluorodeoxyglucose'. Together they form a unique fingerprint.

Cite this